208 related articles for article (PubMed ID: 18551084)
1. Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17beta-estradiol and 2 mg drospirenone HT.
Caruso S; Serra A; Grillo C; De Leo V; Maiolino L; Agnello C; Cianci A
Menopause; 2008; 15(5):967-72. PubMed ID: 18551084
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17beta-estradiol and 2 mg drospirenone: a prospective study.
Caruso S; Serra A; Grillo C; Maiolino L; Agnello C; Di Mari L; Cianci A
Menopause; 2008; 15(5):963-6. PubMed ID: 18391834
[TBL] [Abstract][Full Text] [Related]
3. Olfactometric and rhinomanometric outcomes in post-menopausal women treated with hormone therapy: a prospective study.
Caruso S; Grillo C; Agnello C; Di Mari L; Farina M; Serra A
Hum Reprod; 2004 Dec; 19(12):2959-64. PubMed ID: 15471940
[TBL] [Abstract][Full Text] [Related]
4. Effects of estradiol-drospirenone on ocular and nasal functions in postmenopausal women.
Coksuer H; Ozcura F; Oghan F; Haliloglu B; Coksuer C
Climacteric; 2011 Aug; 14(4):482-7. PubMed ID: 21281244
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
White WB; Pitt B; Preston RA; Hanes V
Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
[TBL] [Abstract][Full Text] [Related]
6. Drospirenone and estradiol: a new option for the postmenopausal woman.
Archer DF
Climacteric; 2007 Feb; 10 Suppl 1():3-10. PubMed ID: 17364592
[TBL] [Abstract][Full Text] [Related]
7. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers WH
Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
[TBL] [Abstract][Full Text] [Related]
8. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
Palacios S; Foidart JM; Genazzani AR
Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
[TBL] [Abstract][Full Text] [Related]
10. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
Foidart JM; Faustmann T
Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
[TBL] [Abstract][Full Text] [Related]
11. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women.
Cayan F; Dilek U; Pata O; Dilek S
J Sex Med; 2008 Jan; 5(1):132-8. PubMed ID: 17961145
[TBL] [Abstract][Full Text] [Related]
14. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium.
Lima SM; Reis BF; Yamada SS; Postigo S; Grande RM; Botogoski SR; Campaner AB; Hueb CK; Galvão MA
Climacteric; 2011 Oct; 14(5):551-7. PubMed ID: 21469974
[TBL] [Abstract][Full Text] [Related]
15. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris.
Knuuti J; Kalliokoski R; Janatuinen T; Hannukainen J; Kalliokoski KK; Koskenvuo J; Lundt S
Am J Cardiol; 2007 Jun; 99(12):1648-52. PubMed ID: 17560868
[TBL] [Abstract][Full Text] [Related]
16. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density.
Panoulis C; Lambrinoudaki I; Vourtsi A; Augoulea A; Kaparos G; Aravantinos L; Christodoulakos G; Creatsas G
Climacteric; 2009 Jun; 12(3):240-7. PubMed ID: 19387881
[TBL] [Abstract][Full Text] [Related]
17. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
Rübig A
Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248
[TBL] [Abstract][Full Text] [Related]
18. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
19. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause.
Casanova G; Radavelli S; Lhullier F; Spritzer PM
Fertil Steril; 2009 Aug; 92(2):605-12. PubMed ID: 18706557
[TBL] [Abstract][Full Text] [Related]
20. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
